Universal Beteiligungs und Servicegesellschaft mbH Takes $875,000 Position in Sarepta Therapeutics, Inc. $SRPT

Universal Beteiligungs und Servicegesellschaft mbH bought a new position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 45,418 shares of the biotechnology company’s stock, valued at approximately $875,000.

A number of other large investors have also bought and sold shares of SRPT. Public Employees Retirement System of Ohio raised its position in Sarepta Therapeutics by 2.2% in the 2nd quarter. Public Employees Retirement System of Ohio now owns 28,792 shares of the biotechnology company’s stock valued at $492,000 after purchasing an additional 607 shares during the last quarter. State of Michigan Retirement System increased its stake in shares of Sarepta Therapeutics by 3.1% in the second quarter. State of Michigan Retirement System now owns 23,600 shares of the biotechnology company’s stock valued at $404,000 after buying an additional 700 shares in the last quarter. Thrivent Financial for Lutherans raised its holdings in shares of Sarepta Therapeutics by 3.3% in the second quarter. Thrivent Financial for Lutherans now owns 23,140 shares of the biotechnology company’s stock valued at $396,000 after buying an additional 744 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in Sarepta Therapeutics by 25.4% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,042 shares of the biotechnology company’s stock worth $69,000 after buying an additional 819 shares in the last quarter. Finally, New York Life Investment Management LLC lifted its position in Sarepta Therapeutics by 10.0% during the 2nd quarter. New York Life Investment Management LLC now owns 10,623 shares of the biotechnology company’s stock worth $182,000 after buying an additional 966 shares in the last quarter. 86.68% of the stock is currently owned by institutional investors.

Sarepta Therapeutics Trading Down 4.2%

Shares of NASDAQ SRPT opened at $20.34 on Monday. Sarepta Therapeutics, Inc. has a fifty-two week low of $10.41 and a fifty-two week high of $120.05. The firm has a market capitalization of $2.13 billion, a P/E ratio of -6.76, a P/E/G ratio of 0.50 and a beta of 0.39. The company has a debt-to-equity ratio of 0.78, a current ratio of 2.95 and a quick ratio of 1.79. The company’s 50 day simple moving average is $21.56 and its 200 day simple moving average is $19.91.

Sarepta Therapeutics (NASDAQ:SRPT) last released its earnings results on Monday, November 3rd. The biotechnology company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.15). The business had revenue of $399.36 million for the quarter, compared to analyst estimates of $331.51 million. Sarepta Therapeutics had a negative return on equity of 4.85% and a negative net margin of 11.25%.Sarepta Therapeutics’s revenue was down 14.5% on a year-over-year basis. During the same period in the prior year, the firm posted $0.62 EPS. On average, analysts predict that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current year.

Insider Activity

In related news, COO Ian Michael Estepan sold 13,187 shares of Sarepta Therapeutics stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $22.31, for a total transaction of $294,201.97. Following the completion of the sale, the chief operating officer directly owned 193,300 shares of the company’s stock, valued at $4,312,523. The trade was a 6.39% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 7.60% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several research firms have weighed in on SRPT. Guggenheim lowered their price objective on shares of Sarepta Therapeutics from $22.00 to $19.00 and set a “buy” rating for the company in a research report on Wednesday, November 5th. Wedbush increased their price target on shares of Sarepta Therapeutics from $32.00 to $34.00 and gave the company an “outperform” rating in a research note on Friday, January 23rd. Bank of America raised their price target on shares of Sarepta Therapeutics from $16.00 to $18.00 and gave the company an “underperform” rating in a report on Wednesday, October 22nd. Piper Sandler upped their price objective on Sarepta Therapeutics from $15.00 to $16.00 and gave the stock a “neutral” rating in a report on Thursday, October 30th. Finally, Royal Bank Of Canada increased their price objective on Sarepta Therapeutics from $16.00 to $18.00 and gave the company a “sector perform” rating in a research report on Thursday, January 8th. Nine investment analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and six have given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $33.84.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.